Identification of New Markers in the Hypereosinophilic Syndrome
Not Applicable
Completed
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Biological: biologie sample
- Registration Number
- NCT01713504
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
- dated and signed informed consent
- virale serology negative or negative result less than 6 months
- virale serology negative for HBV or vaccinated patient
- insured
- virale serology negative or negative result less than 6 months
- negative pregnancy test or female menopause for at least 1 year
Exclusion Criteria
- subject enable adult, under guardianship or under protective measures of justice
- Refusal or inability to give informed consent
- The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Hypereosinophilic syndrome unexplained biologie sample - Hypereosinophilic syndrome explained biologie sample - Normal rate of eosinophilic biologie sample -
- Primary Outcome Measures
Name Time Method The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia. one month after patient inclusion
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHRU, Hôpital Claude Huriez
🇫🇷Lille, Nord, France